Alnylam Pharmaceuticals (ALNY) Presents Vutrisiran ATTR-CM Data at ACC.26 [Yahoo! Finance]
Alnylam Pharmaceuticals, Inc. (ALNY)
Last alnylam pharmaceuticals, inc. earnings: 2/6 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.alnylam.com/investor-overview
Company Research
Source: Yahoo! Finance
presented new clinical and real-world data at the American College of Cardiology's Annual Scientific Session/ACC.26 regarding its cardiovascular portfolio. The findings highlight the benefits of vutrisiran, which is an RNAi therapeutic that silences transthyretin/TTR at the source, for patients with transthyretin-mediated amyloidosis with cardiomyopathy/ATTR-CM. Data from the HELIOS-B analysis showed that vutrisiran improved health-related quality of life and functional outcomes, with treatment effects in older patients appearing comparable to those observed in individuals more than a decade younger. The presentation detailed vutrisiran's efficacy across the disease spectrum, including those with advanced illness and diastolic dysfunction. Regarding the hypertension pipeline, Alnylam shared pooled Phase 2 safety data for zilebesiran, an investigational RNAi therapeutic designed to provide continuous blood pressure control through biannual dosing. The results support the ongoing ev
Show less
Read more
Impact Snapshot
Event Time:
ALNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALNY alerts
High impacting Alnylam Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ALNY
News
- 5 Biotechs That Big Pharma Could Snap Up as Oncology M&A Heats Up [Yahoo! Finance]Yahoo! Finance
- New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management [Yahoo! Finance]Yahoo! Finance
- New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension ManagementBusiness Wire
- Alnylam (ALNY) Targets 25% CAGR with Innovative Therapies [Yahoo! Finance]Yahoo! Finance
- Alnylam Pharmaceuticals (ALNY) had its "buy" rating reaffirmed by Chardan Capital. They now have a $425.00 price target on the stock.MarketBeat
ALNY
Earnings
- 2/12/26 - Beat
ALNY
Sec Filings
- 4/6/26 - Form ARS
- 4/6/26 - Form DEF
- 4/6/26 - Form DEFA14A
- ALNY's page on the SEC website